GLENMARK · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 52/100 — Quality 73 · Valuation 24 · Growth 21 · Momentum 100
| Share price | ₹2,239.50 |
| Market cap | ₹60,319 Cr |
| P/E ratio | 56.5 |
| P/B ratio | 6.3 |
| ROE | 11.9% |
| ROCE | 15.9% |
| Dividend yield | 0.23% |
| Book value | ₹339.57 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹16,983 Cr | ₹1,362 Cr | 27.0% |
| 2025 | ₹13,322 Cr | ₹1,047 Cr | 18.0% |
| 2024 | ₹11,813 Cr | ₹-1,434 Cr | 10.0% |
| 2023 | ₹11,583 Cr | ₹377 Cr | 14.0% |
| 2022 | ₹12,305 Cr | ₹994 Cr | 19.0% |
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topica